Phenoxybenzamine

Phenoxybenzamine
Clinical data
Trade names	Dibenzyline
AHFS/Drugs.com	Monograph
MedlinePlus	a682059
Pregnancy; category	AU: B2; ;
Routes of; administration	Oral
ATC code	C04AX02 (WHO) ;
Pharmacokinetic data
Elimination half-life	24 hours
Identifiers
	IUPAC name (RS)-N-Benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine;
CAS Number	59-96-1 ;
PubChem CID	4768;
IUPHAR/BPS	7268;
DrugBank	DB00925 ;
ChemSpider	4604 ;
UNII	0TTZ664R7Z;
KEGG	D08358 ;
ChEMBL	ChEMBL753 ;
CompTox Dashboard (EPA)	DTXSID0023458 ;
ECHA InfoCard	100.000.406
Chemical and physical data
Formula	C18H22ClNO
Molar mass	303.83 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES ClCCN(C(COc1ccccc1)C)Cc2ccccc2;
	InChI InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3 ; Key:QZVCTJOXCFMACW-UHFFFAOYSA-N ;
	(verify)

Phenoxybenzamine (PBZ,^[1] marketed under the trade names Dibenzyline and Dibenyline) is a non-selective, irreversible alpha blocker.

^ Bradley K. "Clinical Guideline: Phaeochromocytoma Diagnosis and Management" (PDF). University Hospitals Bristol. NHS Foundation Trust. Archived from the original (PDF) on 25 March 2023.